MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

An Efficacy and Safety Study of Topiramate in the Treatment of Alcohol Dependence

Phase 2
Completed
Conditions
Alcoholism
First Posted Date
2005-09-21
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
371
Registration Number
NCT00210925

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Phase 3
Completed
Conditions
Erectile Dysfunction
First Posted Date
2005-09-21
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1067
Registration Number
NCT00210704

A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-09-21
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
748
Registration Number
NCT00210717

A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation

Phase 3
Completed
Conditions
Sexual Dysfunction
Ejaculation
First Posted Date
2005-09-21
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
199
Registration Number
NCT00210613

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Phase 2
Completed
Conditions
Anemia
Kidney Diseases
First Posted Date
2005-09-21
Last Posted Date
2011-05-23
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
67
Registration Number
NCT00210743

Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)

Phase 4
Terminated
Conditions
Anemia
First Posted Date
2005-09-21
Last Posted Date
2011-05-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1432
Registration Number
NCT00211120

A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-09-21
Last Posted Date
2011-05-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
203
Registration Number
NCT00210769

A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

Completed
Conditions
Pure Red-cell Aplasia
Interventions
First Posted Date
2005-09-21
Last Posted Date
2013-04-30
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
124
Registration Number
NCT00211068

A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

Completed
Conditions
Pure Red-cell Aplasia
Interventions
Other: No intervention
First Posted Date
2005-09-21
Last Posted Date
2013-04-30
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
52
Registration Number
NCT00211042
© Copyright 2025. All Rights Reserved by MedPath